Literature DB >> 28752856

Multiple sclerosis: Treatment of cognitive impairment in secondary progressive MS.

Anthony Feinstein1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28752856     DOI： 10.1038/nrneurol.2017.109

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis.

Authors:  L B Krupp; C Christodoulou; P Melville; W F Scherl; L-Y Pai; L R Muenz; D He; R H B Benedict; A Goodman; S Rizvi; S R Schwid; B Weinstock-Guttman; H J Westervelt; H Wishart
Journal:  Neurology       Date:  2011-04-26       Impact factor: 9.910

Review 2.  Treatment of progressive multiple sclerosis: what works, what does not, and what is needed.

Authors:  Anthony Feinstein; Jenny Freeman; Albert C Lo
Journal:  Lancet Neurol       Date:  2015-02       Impact factor: 44.182

Review 3.  The link between multiple sclerosis and depression.

Authors:  Anthony Feinstein; Sandra Magalhaes; Jean-Francois Richard; Blair Audet; Craig Moore
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

4.  The relationship between disability and depression in multiple sclerosis: the role of uncertainty, coping, and hope.

Authors:  S G Lynch; D C Kroencke; D R Denney
Journal:  Mult Scler       Date:  2001-12       Impact factor: 6.312

5.  A dysexecutive syndrome of the medial thalamus.

Authors:  Daniela Liebermann; Christoph J Ploner; Antje Kraft; Ute A Kopp; Florian Ostendorf
Journal:  Cortex       Date:  2011-11-19       Impact factor: 4.027

Review 6.  Minimal neuropsychological assessment of MS patients: a consensus approach.

Authors:  Ralph H B Benedict; Jill S Fischer; Cate J Archibald; Peter A Arnett; William W Beatty; Julie Bobholz; Gordon J Chelune; John D Fisk; Dawn W Langdon; Lauren Caruso; Fred Foley; Nicholas G LaRocca; Lindsey Vowels; Amy Weinstein; John DeLuca; Stephen M Rao; Frederick Munschauer
Journal:  Clin Neuropsychol       Date:  2002-08       Impact factor: 3.535

7.  Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Authors:  Sarah L Minden; Anthony Feinstein; Rosalind C Kalb; Deborah Miller; David C Mohr; Scott B Patten; Christopher Bever; Randolph B Schiffer; Gary S Gronseth; Pushpa Narayanaswami
Journal:  Neurology       Date:  2013-12-27       Impact factor: 9.910

Review 8.  Cognitive impairment in multiple sclerosis.

Authors:  Nancy D Chiaravalloti; John DeLuca
Journal:  Lancet Neurol       Date:  2008-12       Impact factor: 44.182

9.  Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial.

Authors:  Dennis Chan; Sophie Binks; Jennifer M Nicholas; Chris Frost; M Jorge Cardoso; Sebastien Ourselin; David Wilkie; Richard Nicholas; Jeremy Chataway
Journal:  Lancet Neurol       Date:  2017-06-07       Impact factor: 44.182

10.  Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis.

Authors:  Ralph Hb Benedict; John DeLuca; Glenn Phillips; Nicholas LaRocca; Lynn D Hudson; Richard Rudick
Journal:  Mult Scler       Date:  2017-02-16       Impact factor: 6.312
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.